APOB and homozygous familial hypercholesterolemia: To further elucidate the physiological effect of ANGPTL3 inhibition on LDL-C lowering, we investigated apoB-containing lipoprotein kinetics in 4 patients with hoFH before and after treatment with evinacumab, a fully human monoclonal antibody against ANGPTL3.